Cohance Lifesciences Limited Financial Ratios
COHANCE · Healthcare · Current price ₹462.35
P/E ratio
98.6x
P/B ratio
4.4x
ROE
4.6%
ROCE
5.7%
Debt / Equity
0.10
Dividend yield
1.4%
Ratio reference
| Ratio | Value | What it means |
|---|---|---|
| P/E | 98.6x | Price paid per ₹1 of annual earnings — lower is cheaper (context-dependent). |
| P/B | 4.4x | Price relative to book value — <1 can signal deep value or trouble. |
| ROE | 4.6% | Return on equity — how much profit the company earns on shareholder capital. |
| ROCE | 5.7% | Return on capital employed — efficiency including debt. >15% is strong. |
| D/E | 0.10 | Leverage — higher means more debt-funded, riskier in downturns. |
Model it yourself — PEG Ratio Calculator
Opens pre-filled with Cohance Lifesciences Limited's latest numbers.
Cohance Lifesciences Limited profitability
Cohance Lifesciences Limited generates a return on equity of 4.6% and a return on capital employed of 5.7%. An ROE consistently above 15% usually points to a quality business with a durable advantage; below 10% suggests weak profitability or a capital-heavy model.
Leverage & valuation
With a debt-to-equity of 0.10 and a P/E of 98.6x, Cohance Lifesciences Limited is conservatively financed. Our overall business-quality score for the company is 3.0 / 10.
Understand the ratios
More on Cohance Lifesciences Limited
DocStoX estimates are computed from reported financials, for informational purposes only, not investment advice. Consult a SEBI-registered advisor before investing.